<SEC-DOCUMENT>0001564590-21-047407.txt : 20210909
<SEC-HEADER>0001564590-21-047407.hdr.sgml : 20210909
<ACCEPTANCE-DATETIME>20210909073123
ACCESSION NUMBER:		0001564590-21-047407
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210909
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210909
DATE AS OF CHANGE:		20210909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECISION BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001357874
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38841
		FILM NUMBER:		211243518

	BUSINESS ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
		BUSINESS PHONE:		919-314-5512

	MAIL ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dtil-8k_20210909.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-09-09T11:01:47.1822315+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 51282faf8f2d4501adafd10e1fd28fc8 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dtil="http://precisionbiosciences.com/20210909" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
dtil-8k_20210909.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001357874_20210909_20210909">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001357874_20210909_20210909">0001357874</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="dtil-20210909.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001357874_20210909_20210909">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-09</xbrli:startDate>
					<xbrli:endDate>2021-09-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001357874_20210909_20210909">8-K</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001357874_20210909_20210909" format="ixt:datemonthdayyearen">September 9, 2021</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001357874_20210909_20210909">Precision BioSciences, Inc.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityFileNumber" contextRef="C_0001357874_20210909_20210909">001-38841</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001357874_20210909_20210909">20-4206017</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressAddressLine1" contextRef="C_0001357874_20210909_20210909">302 East Pettigrew St.</ix:nonNumeric>, <ix:nonNumeric id="F_000014" name="dei:EntityAddressAddressLine2" contextRef="C_0001357874_20210909_20210909">Suite A-100</ix:nonNumeric>, <ix:nonNumeric id="F_000015" name="dei:EntityAddressCityOrTown" contextRef="C_0001357874_20210909_20210909">Durham</ix:nonNumeric>, <ix:nonNumeric id="F_000016" name="dei:EntityAddressStateOrProvince" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:stateprovnameen">North Carolina</ix:nonNumeric> <ix:nonNumeric id="F_000017" name="dei:EntityAddressPostalZipCode" contextRef="C_0001357874_20210909_20210909">27701</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) (Zip Code) </p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000018" name="dei:CityAreaCode" contextRef="C_0001357874_20210909_20210909">919</ix:nonNumeric>) <ix:nonNumeric id="F_000019" name="dei:LocalPhoneNumber" contextRef="C_0001357874_20210909_20210909">314-5512</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:WrittenCommunications" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SolicitingMaterial" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:PreCommencementTenderOffer" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.95%;">
<tr>
<td style="width:25.91%;"></td>
<td style="width:25.95%;"></td>
<td style="width:48.09%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:Security12bTitle" contextRef="C_0001357874_20210909_20210909">Common stock, par value $0.000005 per share</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:TradingSymbol" contextRef="C_0001357874_20210909_20210909">DTIL</ix:nonNumeric></p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:SecurityExchangeName" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> </p>
<p style="margin-top:8pt;border-bottom:Solid 1.5pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric id="F_000006" name="dei:EntityExTransitionPeriod" contextRef="C_0001357874_20210909_20210909" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </p>
<p style="margin-top:8pt;border-bottom:Solid 1.5pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01. Regulation FD Disclosure.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 9, 2021, Precision BioSciences, Inc. (the &#8220;Company&#8221;) issued a press release to announce its first R&#38;D event focused on <span style="font-style:italic;">in vivo</span> gene editing and also announced its license and collaboration agreement with iECURE to develop ARCUS-based gene editing therapies. Copies of the press releases are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated in this Item 7.01 by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in the accompanying press release, the Company will host a live webcast today, Thursday, September 9, 2021 at 8:00 a.m., Eastern Time,<span style="font-size:12pt;color:#000000;"> </span>featuring presentations from Company management as well as featured guest speakers and will outline the Company&#8217;s development strategy to advance its <span style="font-style:italic;">in vivo</span> gene editing portfolio. The agenda will include an overview of ARCUS, the Company&#8217;s proprietary platform for <span style="font-style:italic;">in vivo</span> gene correction, new pre-clinical data, timelines for leading <span style="font-style:italic;">in vivo</span> gene editing programs, and updates from academic and industry collaborators. <span style="color:#000000;">Access to the live webcast and the accompanying presentation materials, including a copy of the Company&#8217;s corporate deck, will be available in the &#8220;Investors &#38; Media&#8221; portion of the Company&#8217;s website at </span><span style="text-decoration:underline;color:#000000;">https://investor.precisionbiosciences.com</span><span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information in this Item 7.01 (including Exhibits 99.1 and 99.2) of this Form 8-K is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01. Other Events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 9, 2021, the Company provided an update regarding its clinical development strategy for its <span style="font-style:italic;">in vivo</span> gene editing pipeline and also announced its license and collaboration agreement with iECURE to develop ARCUS-based gene editing therapies. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that three of its preclinical programs will advance to investigational new drug (&#8220;IND&#8221;)/clinical trial application (&#8220;CTA&#8221;) in the next three years:</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">As part of an agreement to expedite development, iECURE expects to advance the Company&#8217;s PBGENE-PCSK9 candidate for familial hypercholesterolemia (&#8220;FH&#8221;) through Phase 1 clinical studies with CTA filing expected as early as 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">The Company has initiated IND-enabling activities and expects to submit an IND application for PBGENE-PH1 for primary hyperoxaluria type 1 (&#8220;PH1&#8221;) in 2023.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">The Company will pursue clinical development of its PBGENE-HBV candidate for chronic hepatitis B virus (&#8220;HBV&#8221;) and expects to submit an IND/CTA in 2024.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has also announced that it has signed a license and collaboration agreement with iECURE, a mutation-agnostic <span style="font-style:italic;">in vivo</span> gene editing company striving to cure devastating diseases with high unmet need, co-founded by James M. Wilson, M.D., Ph.D. Using the Company&#8217;s PCSK9-directed ARCUS nuclease, iECURE plans to advance the Company&#8217;s PBGENE-PCSK9 candidate into a Phase 1 study in FH and gains access to the Company&#8217;s PCSK9-directed ARCUS nuclease to develop four other pre-specified gene insertion therapies for genetic diseases, focusing initially on liver diseases. The Company will retain rights to PBGENE-PCSK9, including for FH and all products developed for genetic indications except those licensed to iECURE. In return for its license grant, the Company will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments on sales of iECURE products developed with ARCUS.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presentations from the Company&#8217;s<span style="font-style:italic;"> in vivo</span> Gene Editing R&#38;D event will highlight the Company&#8217;s clinical development strategy and updates on the following wholly-owned and partnered preclinical programs using ARCUS-mediated editing:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Featured Preclinical Data</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for Gene Insertion into the PCSK9 locus: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">Due to the unique type of cut made by ARCUS nucleases, we believe ARCUS may be better suited for gene insertion than CRISPR-based gene editing tools. In non-human primates (&#8220;NHPs&#8221;), ARCUS was observed to be more efficient than CRISPR at inserting a Factor IX transgene into the PCSK9 locus. The Factor IX transgene is responsible for making the coagulation Factor IX protein associated with hemophilia B bleeding disorder.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for Chronic HBV (PBGENE-HBV):</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;"> Current standard-of-care treatments for HBV suppress viral replication, but often do not clear the virus, leaving covalently closed circular DNA (&#8220;cccDNA&#8221;) and integrated HBV genomes that enable viral persistence. The Company&#8217;s gene editing program for HBV applies ARCUS to knockout this persistent cccDNA and potentially further reduce viral persistence.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New preclinical data to be presented today, and data previously presented at the <span style="Background-color:#FFFFFF;color:#000000;">American Society of Gene &#38; Cell Therapy Annual Meeting, </span>show that ARCUS efficiently targeted and degraded HBV cccDNA <span style="Background-color:#FFFFFF;color:#000000;">in HBV-infected primary human hepatocytes and reduced expression of HBV S-antigen (&#8220;HBsAg&#8221;) by as much as 95%. Similar levels of HBsAg reduction were observed in a newly developed mouse model of HBV infection following administration of ARCUS mRNA using lipid nanoparticle (&#8220;LNP&#8221;) delivery. </span>The Company will pursue clinical development of its PBGENE-HBV candidate using LNP delivery and expects to submit an IND in 2024. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for Mitochondrial Genome Editing</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">: Mitochondrial diseases frequently are caused by pathogenic mutations in the mitochondrial genome that reduce the ability of mitochondria to convert food and oxygen into energy to sustain life and support organ function. Mitochondrial diseases affect approximately 1 in 5,000 individuals. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent preclinical studies used mitochondrial-targeted ARCUS (&#8220;mitoARCUS&#8221;) to selectively eliminate mutant mitochondrial genomes that cause disease in cell and animal models. In work conducted by the Company, a hybrid cell model with a mixture of wild-type (healthy) and mutant mitochondrial genomes, a single treatment with mitoARCUS mRNA converted the cells to &#62;99% wild-type. <span style="Background-color:#FFFFFF;color:#000000;">Work led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine and in a mouse model of mitochondrial disease and </span><span style="Background-color:#FFFFFF;">published online in </span><span style="font-style:italic;Background-color:#FFFFFF;">Nature Communications</span><span style="Background-color:#FFFFFF;color:#000000;"> on May 28, 2021, found that mitoARCUS delivered by AAV effectively targeted and depleted mutant mitochondrial genomes in multiple tissues. No editing of potential nuclear off-target sites could be detected, and liver and skeletal muscle showed robust elimination of mutant mtDNA with concomitant restoration of markers of mitochondrial function. </span></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for FH (PBGENE-PCSK9): </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;">The Company&#8217;s gene editing program for FH seeks to knockout expression of the PCSK9 gene. As published by Wang et al. in </span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">Molecular Therapy</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;"> in June 2021, &#8220;Long-term Stable Reduction of Low-density Lipoprotein in Nonhuman Primates Following </span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;color:#000000;">In Vivo</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;"> Genome Editing,&#8221; PBGENE-PCSK9 is supported by extensive NHP data over a three-year period, which demonstrates a long-term, stable edit accompanied by up to an 82% reduction from baseline in PCSK9 levels and up to a 62% reduction in LDL levels. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data will be presented on the clinical nuclease which is expected to be delivered by AAVrh79 in a Phase 1 clinical study to be conducted by iECURE. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for PH1 (PBGENE-PH1):</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;"> The Company&#8217;s gene editing program for PH1 applies ARCUS to knockout the well-characterized HAO1 gene to prevent the production of a toxic metabolite called oxalate that causes extremely severe and potentially fatal kidney stone accumulation in patients. <br /></span></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NHP data supporting this approach has shown, on average, a 98.0% reduction in HAO1 mRNA and a 97.9% reduction in the encoded protein after a single administration of an AAV vector encoding ARCUS. Compared to published results with siRNAs targeting HAO1, the Company&#8217;s approach appeared to provide an improved metabolic profile with the potential for long-term benefit from a single dose. The Company has initiated IND-enabling activities and expects to submit an IND application for this program in 2023 using LNP delivery. </p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#000000;">ARCUS for Duchenne Muscular Dystrophy (&#8220;DMD&#8221;) (PBGENE-DMD):</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;"> ARCUS genome editing has previously been shown to increase expression of a shortened version of dystrophin in cultured myoblasts from a DMD patient. The approach uses two ARCUS nucleases delivered by a single AAV to simultaneously cut and delete a large segment of the dystrophin gene that encodes exons 45 through 55 of dystrophin &#8211; a region of the gene that accounts for more than 50% of DMD-causing mutations.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company and Lilly announced an exclusive license agreement to utilize ARCUS genome editing for the research and development of up to six potential <span style="font-style:italic;">in vivo</span> targets for genetic disorders. The collaboration initially included three gene targets, with the lead program targeting the dystrophin gene responsible for DMD (<span style="font-weight:bold;">PBGENE-DMD</span>). In addition, the Company will use ARCUS for one liver-directed target (<span style="font-weight:bold;">PBGENE-LLY2</span>) and one CNS-directed target (<span style="font-weight:bold;">PBGENE-LLY3</span>).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s balance of cash and cash equivalents is approximately $167 million as of August 31, 2021. This estimate is unaudited and does not present all information necessary for an understanding of the Company&#8217;s financial condition as of August 31, 2021, and its results of operations for the period then ended. The Company continues to expect that existing cash and cash equivalents will be sufficient to fund planned operations into 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements in this Current Report on Form 8-K regarding management&#8217;s future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited, to statements regarding the Company's expected cash balance, statements regarding the further development and potential of our ARCUS platform, the clinical development and timeline of PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV, our agreement with iECURE and the potential clinical development and benefits thereunder, and our agreement with Lilly and the potential clinical development and benefits thereunder. Forward-looking statements may be identified by words such as &#8220;anticipates,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan to,&#8221; &#8220;potential,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as such factors may be updated from time to time in the Company&#8217;s other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), which filings are accessible on the SEC&#8217;s website at www.sec.gov and the Investors &#38; Media page of the Company&#8217;s website at https://investor.precisionbiosciences.com. All forward-looking statements speak only as of the date of this Current Report on Form 8-K and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01.<span style="margin-left:46pt;">Financial Statements and Exhibits. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />No.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex991_96.htm"><span style="text-decoration:underline;">Press release of Precision BioSciences, Inc. regarding R&#38;D Event, dated September 9, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex992_97.htm"><span style="text-decoration:underline;">Press release of Precision BioSciences, Inc. regarding iECURE License and Collaboration Agreement, dated September 9, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8239;Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: September 9, 2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Kane</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dtil-ex991_96.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex991_96.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences Outlines Clinical Development Strategy for <font style="font-style:italic;">In Vivo</font> Gene Editing Pipeline</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Announced Licensing and Collaboration Agreement with iECURE to Advance PCSK9 Knockout Program for Familial Hypercholesterolemia Through Phase 1; iECURE Also Receives License to Develop Four ARCUS-Based Gene Insertion Programs</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.36%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Featured Preclinical Data Demonstrating Precision and Versatility of ARCUS Editing Platform, Including First Presentation of ARCUS-Mediated Gene Insertion in Non-Human Primates</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">-</font></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Gene Editing Event Broadcast at 8:00 am ET Includes Presentation by James M. Wilson, M.D., Ph.D., Professor in the Departments of Medicine and Pediatrics, Perelman School of Medicine, University of Pennsylvania and Chief Scientific Advisor of iECURE</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">DURHAM, N.C., September 9, 2021 --<font style="font-weight:normal;"> Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and </font><font style="font-style:italic;font-weight:normal;">in vivo</font><font style="font-weight:normal;"> gene correction therapies with its ARCUS&#174; genome editing platform, today provided strategic business updates on its </font><font style="font-style:italic;font-weight:normal;">in vivo</font><font style="font-weight:normal;"> gene editing pipeline during the Company&#8217;s first gene editing R&amp;D event.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Gene editing promises to fundamentally reshape the treatment landscape across numerous therapeutic categories. Today&#8217;s <font style="font-style:italic;">in vivo</font> gene editing R&amp;D event showcases the power of our ARCUS genome editing platform &#8211; including key demonstrations of capabilities, such as gene insertion and mitochondrial DNA gene editing &#8211; which offers distinct advantages in this emerging field,&#8221; commented Matt Kane, CEO and co-founder of Precision BioSciences. &#8220;We are excited to announce a new collaboration with iECURE which we expect to help us expedite clinical validation of the ARCUS platform for both gene knockout and gene insertion.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Today, we are excited to share additional data highlighting the precision and versatility of our ARCUS platform, which is designed to enable safe, specific and efficient gene editing. Since ARCUS can be delivered via AAV or LNP, it has potential utility in treating diseases in the liver as well as many genetic diseases that affect tissues beyond the liver. In addition, the unique enzymology of ARCUS enables it to make complex gene insertion and gene repair edits more efficiently than other editing platforms,&#8221; said Derek Jantz, Ph.D., Chief Scientific Officer and co-founder of Precision. &#8220;We believe these unique attributes of ARCUS support its differentiation for <font style="font-style:italic;">in vivo</font> use and its potential to treat a broader range of genetic diseases than other editing technologies. We are very excited about our near-term pipeline and expect ARCUS to deliver on its full promise as we take on more challenging programs.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision expects that three of its preclinical programs will advance to investigational new drug (IND)/clinical trial application (CTA) in the next three years:</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">As part of an agreement to expedite development, iECURE expects to advance Precision&#8217;s </font><font style="font-weight:bold;color:#000000;">PBGENE-PCSK9 </font><font style="color:#000000;">candidate for familial hypercholesterolemia (FH) through Phase 1 clinical studies with CTA filing expected as early as 2022.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Precision has initiated IND-enabling activities and expects to submit an IND application for </font><font style="font-weight:bold;color:#000000;">PBGENE-PH1</font><font style="color:#000000;"> for primary hyperoxaluria type 1 (PH1) in 2023.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">Precision will pursue clinical development of its </font><font style="font-weight:bold;color:#000000;">PBGENE</font><font style="font-weight:bold;color:#000000;">-HBV</font><font style="color:#000000;"> candidate </font><font style="color:#000000;">for chronic </font><font style="color:#000000;">h</font><font style="color:#000000;">epatitis B virus (HBV)</font><font style="color:#000000;"> </font><font style="color:#000000;">and expects to submit an IND</font><font style="color:#000000;">/CTA</font><font style="color:#000000;"> in 2024.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Announced today in a separate release, Precision BioSciences has signed a license and collaboration agreement with iECURE, a mutation-agnostic <font style="font-style:italic;">in vivo</font> gene editing company striving to cure devastating diseases with high unmet need, co-founded by James M. Wilson, M.D., Ph.D. Using Precision&#8217;s PCSK9-directed ARCUS nuclease, iECURE plans to advance Precision&#8217;s PBGENE-PCSK9 candidate into a Phase 1 study in FH and gain access to Precision&#8217;s PCSK9-directed ARCUS nuclease to develop four other pre-specified gene insertion therapies for genetic diseases, focusing initially on liver diseases. Precision will retain rights to PBGENE-PCSK9, including for FH and all products developed for genetic indications except those licensed to iECURE. In return for its license grant, Precision will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments on sales of iECURE products developed with ARCUS.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk82029211"></a>Presentations from Precision&#8217;s <font style="font-style:italic;">in vivo</font> Gene Editing R&amp;D event will highlight the Company&#8217;s clinical development strategy and updates on the following wholly-owned and partnered preclinical programs using ARCUS-mediated editing:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Featured Preclinical Data</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for Gene Insertion into the PCSK9 locus: </font><font style="color:#000000;">Due to the unique type of cut made by ARCUS nucleases, we believe ARCUS may be better suited for gene insertion than CRISPR-based gene editing tools. In non-human primates (NHPs), ARCUS was observed to be more efficient than CRISPR at inserting a Factor IX transgene into the PCSK9 locus. The Factor IX transgene is responsible for making the coagulation Factor IX protein associated with hemophilia B bleeding disorder.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Research conducted by the Gene Therapy Program has shown ARCUS is capable of precise edits that can be applied broadly across genetic diseases in a mutation-dependent manner,&#8221; said Dr. James M. Wilson. &#8220;Additionally, as reported today, ARCUS has demonstrated highly efficient gene insertion with a PCSK9-directed nuclease that will be foundational to iECURE in addressing rare genetic diseases, as well as long-term durability reflecting its curative potential with a single administration. Taken together, these findings continue to support what we have learned over years of collaborating with Precision: that the unique properties of ARCUS are differentiated versus other tools in this field.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for Chronic HBV (PBGENE-HBV):</font><font style="color:#000000;"> Current standard-of-care treatments for HBV suppress viral replication, but often do not clear the virus, leaving covalently closed circular DNA (cccDNA) and integrated HBV genomes that enable viral persistence. Precision&#8217;s gene editing program for HBV applies ARCUS to knockout this persistent cccDNA and potentially further reduce viral persistence.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New preclinical data to be presented today, and data previously presented at the <font style="Background-color:#FFFFFF;color:#000000;">American Society of Gene &amp; Cell Therapy Annual Meeting, </font>show that ARCUS efficiently targeted and degraded HBV cccDNA <font style="Background-color:#FFFFFF;color:#000000;">in HBV-infected primary human hepatocytes and reduced expression of HBV S-antigen (HBsAg) by as much as 95%. Similar levels of HBsAg reduction were observed in a newly developed mouse model of HBV infection following administration of ARCUS mRNA using lipid nanoparticle (LNP) delivery. </font>Precision will pursue clinical development of its PBGENE-HBV candidate using LNP delivery and expects to submit an IND in 2024. </p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for Mitochondrial Genome Editing</font><font style="color:#000000;">: Mitochondrial diseases frequently are caused by pathogenic mutations in the mitochondrial genome that reduce the ability of mitochondria to convert food and oxygen into energy to sustain life and support organ function. Mitochondrial diseases affect approximately 1 in 5,000 individuals. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk81939715"></a>Recent preclinical studies used mitochondrial-targeted ARCUS (mitoARCUS) to selectively eliminate mutant mitochondrial genomes that cause disease in cell and animal models. In work conducted by Precision BioSciences, a hybrid cell model with a mixture of wild-type (healthy) and mutant mitochondrial genomes, a single treatment with mitoARCUS mRNA converted the cells to &gt;99% wild-type. <font style="Background-color:#FFFFFF;color:#000000;">Work led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine and in a mouse model of mitochondrial disease and </font><font style="Background-color:#FFFFFF;text-decoration:underline;">published online in </font><font style="font-style:italic;Background-color:#FFFFFF;text-decoration:underline;">Nature Communications</font><font style="Background-color:#FFFFFF;color:#000000;"> on May 28, 2021, found that mitoARCUS delivered by AAV effectively targeted and depleted mutant mitochondrial genomes in multiple tissues. No editing of potential nuclear off-target sites could be detected, and liver and skeletal muscle showed robust elimination of mutant mtDNA with concomitant restoration of markers of mitochondrial function. </font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk81759766"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for FH (PBGENE-PCSK9): </font><font style="color:#000000;">Precision&#8217;s gene editing program for FH seeks to knockout expression of the PCSK9 gene. As published by Wang et al. in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Molecular Therapy</font><font style="color:#000000;"> in June 2021, &#8220;Long-term Stable Reduction of Low-density Lipoprotein in Nonhuman Primates Following </font><font style="font-style:italic;color:#000000;">In Vivo</font><font style="color:#000000;"> Genome Editing,&#8221; PBGENE-PCSK9 is supported by extensive NHP data over a three-year period, which demonstrates a long-term, stable edit accompanied by up to an 82% reduction from baseline in PCSK9 levels and up to a 62% reduction in LDL levels. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data will be presented on the clinical nuclease which is expected to be delivered by AAVrh79 in a Phase 1 clinical study to be conducted by iECURE. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for PH1 (PBGENE-PH1):</font><font style="color:#000000;"> Precision&#8217;s gene editing program for PH1 applies ARCUS to knockout the well-characterized HAO1 gene to prevent the production of a toxic metabolite called oxalate that causes extremely severe and potentially fatal kidney stone accumulation in patients. <br /></font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NHP data supporting this approach has shown, on average, a 98.0% reduction in HAO1 mRNA and a 97.9% reduction in the encoded protein after a single administration of an AAV vector encoding ARCUS. Compared to published results with siRNAs targeting HAO1, Precision&#8217;s approach appeared to provide an improved metabolic profile with the potential for long-term benefit from a single dose. Precision has initiated IND-enabling activities and expects to submit an IND application for this program in 2023 using LNP delivery. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;color:#000000;">ARCUS for Duchenne Muscular Dystrophy (DMD) (PBGENE-DMD):</font><font style="color:#000000;"> ARCUS genome editing has previously been shown to increase expression of a shortened version of dystrophin in cultured myoblasts from a DMD patient. The approach uses two ARCUS nucleases delivered by a single AAV to simultaneously cut and delete a large segment of the dystrophin gene that encodes exons 45 through 55 of dystrophin &#8211; a region of the gene that accounts for more than 50% of DMD-causing mutations.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, Precision and Lilly announced an exclusive license agreement to utilize ARCUS genome editing for the research and development of up to six potential <font style="font-style:italic;">in vivo</font> targets for genetic disorders. The collaboration initially included three gene targets, with the lead program targeting the dystrophin gene responsible for DMD (<font style="font-weight:bold;">PBGENE-DMD</font>). In addition, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision will </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use ARCUS for one liver-directed </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">target </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;">PBGENE-LLY2</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> CNS</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-directed</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">target</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (</font><font style="font-weight:bold;">PBGENE-LLY3</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Jantz continued, &#8220;The versatility of our platform offers us the optionality to pursue numerous therapeutic applications through strategic partnerships, enabling us to capture more of the value of the ARCUS technology and accelerate key programs. For example, in addition to rapidly advancing PBGENE-PCSK9 to the clinic, iECURE will provide critical validation of ARCUS&#8217; gene-insertion capabilities. Lilly will help us research ARCUS-mediated editing in muscle and CNS. Even as we aggressively invest in wholly-owned programs, we will continue to leverage collaborations that enable us to explore novel applications of ARCUS and reach patients quicker.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s balance of cash and cash equivalents is approximately $167 million as of August 31, 2021. The Company continues to expect that existing cash and cash equivalents will be sufficient to fund planned operations into 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Call and Webcast Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision's gene editing R&amp;D event is being held today, September 9, 2021, at 8:00 a.m. ET. The dial-in conference call numbers for domestic and international callers are (866) 970-2058 and (873) 415-0216, respectively. The conference ID number for the call is 6376435. Participants may also access the live webcast, including slides, available in the Investors and Media section under <font style="text-decoration:underline;">Events and Presentations</font>. An archived replay of the webcast will be available on Precision's website for one year following the presentation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About ARCUS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCUS<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> is a proprietary genome editing technology discovered and developed by scientists at Precision BioSciences. It uses sequence-specific DNA-cutting enzymes, or nucleases, that are designed to either insert (knock in), remove (knockout), or repair DNA of living cells and organisms. ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae <font style="font-style:italic;">Chlamydomonas reinhardtii</font>&#160;to make highly specific cuts in cellular DNA. Precision's platform and products are protected by a comprehensive portfolio including more than 80 patents to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Precision BioSciences, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS&#174; genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company&#8217;s pipeline consists of multiple &#8220;off-the-shelf&#8221; CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit <font style="text-decoration:underline;">www.precisionbiosciences.com</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the further development and potential of our ARCUS platform, the clinical development and timeline of PBGENE-PCSK9, PBGENE-PH1 and PBGENEHBV, our agreement with iECURE and the potential clinical development and benefits thereunder, our agreement with Lilly and the potential clinical development and benefits thereunder, and our expected use of cash and cash equivalents. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;mission,&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;goal,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;contemplate,&#8221; &#8220;potential,&#8221; or the negative thereof and similar words and expressions.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements are based on management&#8217;s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments and effects of restrictions thereunder; risks associated with raising additional capital; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; our or our collaborators&#8217; ability to identify, develop and commercialize product candidates; pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators&#8217; development of product candidates; our or our collaborators&#8217; ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; our or our collaborators&#8217; ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; our ability to achieve our anticipated operating efficiencies at our manufacturing facility; delays or difficulties in our and our collaborators&#8217; ability to enroll patients; changes in interim &#8220;top-line&#8221; and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate key executives and personnel; market and economic conditions; effects of system failures and security breaches; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events effects of the outbreak of COVID-19, or any pandemic, epidemic or outbreak of an infectious disease; insurance expenses and exposure to uninsured liabilities; effects of tax rules; risks related to ownership of our common stock and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC&#8217;s website at www.sec.gov and the Investors &amp; Media page of our website at investor.precisionbiosciences.com.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Contact:<font style="font-weight:normal;"><br />Alex Kelly</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Alex.Kelly@precisionbiosciences.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maurissa Messier</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Director, Corporate Communications</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Maurissa.Messier@precisionbiosciences.com</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>dtil-ex992_97.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex992_97.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">iECURE to License Precision&#8217;s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"> iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision&#8217;s PBGENE-PCSK9 Candidate for Familial Hypercholesterolemia </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Calibri;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Data for ARCUS-Mediated Gene Insertion to be Presented Today by iECURE Chief Scientific Advisor, James M. Wilson, M.D., Ph.D. at Precision&#8217;s Gene Editing R&amp;D Event </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Durham, NC and Philadelphia, PA, September 9, 2021<font style="font-weight:normal;"> &#8211; Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company developing allogeneic CAR T and </font><font style="font-style:italic;font-weight:normal;">in vivo</font><font style="font-weight:normal;"> gene correction therapies with its ARCUS&#174; genome editing platform, and iECURE, a mutation-agnostic </font><font style="font-style:italic;font-weight:normal;">in vivo</font><font style="font-weight:normal;"> gene editing company striving to cure devastating diseases with high unmet need, today announced a license and collaboration agreement under which iECURE plans to advance Precision&#8217;s PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision&#8217;s PCSK9-directed ARCUS nuclease to develop additional gene editing therapies for genetic diseases, initially targeting liver diseases. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, iECURE plans to file a clinical trial application as early as 2022 to advance the PBGENE-PCSK9 clinical candidate through Phase 1 clinical studies for the treatment of familial hypercholesterolemia (FH). Precision will retain rights to PBGENE-PCSK9, including all products developed for genetic indications with increased risk of severe cardiovascular events such as FH. In return, Precision has granted iECURE a license to use its PCSK9-directed ARCUS nuclease to insert genes into the well-characterized PCSK9 locus to develop treatments for four other pre-specified rare genetic diseases. Precision will receive an equity stake in iECURE and is eligible to receive milestone and royalty payments on sales of iECURE products developed with ARCUS.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to continue working with Jim Wilson under this new <font style="font-style:italic;">in vivo</font> gene editing license and collaboration agreement with iECURE, as iECURE looks to rapidly advance our PBGENE-PCSK9 candidate, file for a clinical trial application in 2022, and use our PCSK9-directed ARCUS nuclease, and its knock-in capabilities, to pursue new treatments for rare genetic diseases,&#8221; said Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder of Precision BioSciences. &#8220;Through this collaboration we expect to gain important clinical validation for <font style="font-style:italic;">in vivo</font> gene editing with ARCUS, while <font style="color:#000000;">retaining rights to this PCSK9-directed nuclease, which we believe offers a safe harbor locus for DNA gene editing knock-in without deleterious effects when the PCSK9 gene is disrupted.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We founded iECURE with the aim of focusing on genetic diseases with significant unmet need that we could target in a mutation-agnostic manner. After evaluating different gene editing technologies and platforms, we believe gene editing with ARCUS, including use of the uniquely designed ARCUS nuclease as a gene insertion tool targeting the PCSK9 gene will help us rapidly advance several candidates to the clinic with the potential to deliver on the promise of highly efficient, specific, and safe gene insertion,&#8221; said Joe Truitt, Chief Executive Officer of iECURE. &#8220;We are excited to partner with Precision on this key pillar of our gene editing strategy, to advance this work for rare genetic diseases.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James M. Wilson, M.D., Ph.D., Chief Scientific Advisor of iECURE and Professor in the Departments of Medicine and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Director, Gene Therapy Program<font style="color:#000000;">,</font><font style="color:#FF0000;"> </font>will present new non-human primate data demonstrating ARCUS-mediated gene addition today, September 9, 2021 during the <font style="text-decoration:underline;">Precision BioSciences gene editing R&amp;D event</font>. Dr. Wilson and his team have demonstrated in non-human primates that it is possible to use ARCUS to insert new genes stably into the PCSK9 locus, which could be used as a potential approach for treating multiple genetic diseases with a single therapeutic strategy.&nbsp;&nbsp; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About ARCUS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCUS&#174; is a proprietary genome editing technology discovered and developed by scientists at Precision BioSciences. It uses sequence-specific DNA-cutting enzymes, or nucleases, that are designed to either insert (knock in), remove (knockout), or repair DNA of living cells and organisms. ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae <font style="font-style:italic;">Chlamydomonas reinhardtii</font> to make highly specific cuts in cellular DNA. Precision's platform and products are protected by a comprehensive portfolio including more than 80 patents to date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Precision BioSciences, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS&#174;<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company&#8217;s pipeline consists of multiple &#8220;off-the-shelf&#8221; CAR T immunotherapy clinical candidates and several </font><font style="font-style:italic;Background-color:#FFFFFF;">in vivo</font><font style="Background-color:#FFFFFF;"> gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit&#160;</font><font style="Background-color:#FFFFFF;text-decoration:underline;">www.precisionbiosciences.com</font><font style="Background-color:#FFFFFF;">.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About iECURE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iECURE is an <font style="font-style:italic;">in vivo </font>gene editing company striving to cure liver disorders with high unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania&#8217;s Gene Therapy Program. <font style="color:#000000;">Using </font><font style="font-style:italic;color:#000000;">in vivo </font><font style="color:#000000;">editing, our methods focus on inserting functioning genes into patients&#8217; genomes, which offers long-term, stable expression of those genes. </font>With our team&#8217;s proven track record, reversing the course of these devastating disorders is now hopefully within reach.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial disclosure: The University of Pennsylvania and Dr. James Wilson hold equity interests in iECURE, receive significant sponsored research support from the company, and will be entitled to receive licensing revenues from iECURE based on successful technology development and commercialization of the licensed technology.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Precision&#8217;s Forward-Looking Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the Private Securities <font style="color:#000000;">Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company&#8217;s agreement with iECURE to develop and commercialize gene editing therapies using the Company&#8217;s PCSK9-directed ARCUS nuclease for cardiovascular and rare genetic diseases, the timing of clinical trials and results therefrom, any future milestones or royalty payments thereunder, the development and commercial potential of ARCUS-mediated gene addition and the potential value of iECURE equity. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">&#8220;target,&#8221; &#8220;mission,&#8221; &#8220;goal,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;contemplate,&#8221; &#8220;potential,&#8221; or the negative thereof and similar words and expressions.</font></p>
<p style="Background-color:#FFFFFF;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements are based on management&#8217;s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments and effects of restrictions thereunder; risks associated with raising additional capital; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; our or our collaborators&#8217; ability to identify, develop and commercialize product candidates; pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators&#8217; development of product candidates; our or our collaborators&#8217; ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; our or our collaborators&#8217; ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; our ability to achieve our anticipated operating efficiencies at our manufacturing facility; delays or difficulties in our and our collaborators&#8217; ability to enroll patients; changes in interim &#8220;top line&#8221; and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate key executives and personnel; market and economic conditions; effects of system failures and security breaches; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events effects of the outbreak of COVID-19, or any pandemic, epidemic or outbreak of an infectious disease; insurance expenses and exposure to uninsured liabilities; effects of tax rules; risks related to ownership of our common stock; and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC&#8217;s website at <font style="text-decoration:underline;color:#000000;">www.sec.gov</font> and the Investors &amp; Media page of our website at investor.precisionbiosciences.com.</p>
<p style="Background-color:#FFFFFF;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="Background-color:#FFFFFF;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences Investor Contact:<font style="font-weight:normal;"><br />Alex Kelly<br />Chief Financial Officer<br /></font><font style="color:#2F80D1;text-decoration:underline;font-weight:normal;">Alex.Kelly@precisionbiosciences.com</font></p>
<p style="Background-color:#FFFFFF;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences Media Contact:<font style="font-weight:normal;"><br />Maurissa Messier<br />Senior Director, Corporate Communications<br /></font><font style="color:#2F80D1;text-decoration:underline;font-weight:normal;">Maurissa.Messier@precisionbiosciences.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">iECURE Contact:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Danielle Cantey</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canale Communications for iECURE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Danielle.cantey@canalecomm.com</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dtil-20210909.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-27T21:42:34.7140590+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 51282faf8f2d4501adafd10e1fd28fc8 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtil="http://precisionbiosciences.com/20210909" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://precisionbiosciences.com/20210909" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://precisionbiosciences.com/20210909/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20210909_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dtil-20210909_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>dtil-20210909_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-27T21:42:34.7140590+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 51282faf8f2d4501adafd10e1fd28fc8 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>dtil-20210909_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-08-27T21:42:34.7140590+00:00 -->
<!-- Version            : 5.0.1.648 -->
<!-- Package ID         : 51282faf8f2d4501adafd10e1fd28fc8 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://precisionbiosciences.com/20210909/role/TemplateLink" xlink:href="dtil-20210909.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="dtil-20210909.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>dtil-8k_20210909_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dtil-20210909.xsd" xlink:type="simple"/>
    <context id="C_0001357874_20210909_20210909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
        </entity>
        <period>
            <startDate>2021-09-09</startDate>
            <endDate>2021-09-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001357874_20210909_20210909" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001357874_20210909_20210909" id="F_000004">0001357874</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001357874_20210909_20210909" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001357874_20210909_20210909" id="F_000002">2021-09-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001357874_20210909_20210909" id="F_000003">Precision BioSciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001357874_20210909_20210909" id="F_000011">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001357874_20210909_20210909" id="F_000010">001-38841</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001357874_20210909_20210909" id="F_000012">20-4206017</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001357874_20210909_20210909" id="F_000013">302 East Pettigrew St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001357874_20210909_20210909" id="F_000014">Suite A-100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001357874_20210909_20210909" id="F_000015">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001357874_20210909_20210909" id="F_000016">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001357874_20210909_20210909" id="F_000017">27701</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001357874_20210909_20210909" id="F_000018">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001357874_20210909_20210909" id="F_000019">314-5512</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001357874_20210909_20210909" id="F_000020">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001357874_20210909_20210909" id="F_000021">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001357874_20210909_20210909" id="F_000022">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001357874_20210909_20210909" id="F_000023">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001357874_20210909_20210909" id="F_000007">Common stock, par value $0.000005 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001357874_20210909_20210909" id="F_000008">DTIL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001357874_20210909_20210909" id="F_000009">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001357874_20210909_20210909" id="F_000005">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001357874_20210909_20210909" id="F_000006">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140469881646616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  09,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Precision BioSciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001357874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.000005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DTIL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-4206017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">302 East Pettigrew St.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A-100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">314-5512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MZCLI4Y#F'MOM    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ ZCLI4YE<G",0!@  G"<  !,
M ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #J.RE3ET4]
M>W@$  ".$0  &               @($,"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ ZCLI4Y^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  &A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dtil-8k_20210909.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dtil-8k_20210909.htm">dtil-8k_20210909.htm</File>
    <File>dtil-20210909.xsd</File>
    <File>dtil-20210909_lab.xml</File>
    <File>dtil-20210909_pre.xml</File>
    <File>dtil-ex991_96.htm</File>
    <File>dtil-ex992_97.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dtil-8k_20210909.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "dtil-8k_20210909.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dtil-20210909_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dtil-20210909_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dtil-20210909.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dtil",
   "nsuri": "http://precisionbiosciences.com/20210909",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "dtil-8k_20210909.htm",
      "contextRef": "C_0001357874_20210909_20210909",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "dtil-8k_20210909.htm",
      "contextRef": "C_0001357874_20210909_20210909",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://precisionbiosciences.com/20210909/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-21-047407-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-047407-xbrl.zip
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M32%%]I4X6M_TA]^2.G)9#D)1G3*UIZA5\" @O1R8_T]X+HS?&9[Y.FZ.9<=
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M9(@X]9X3^;YESXP<'77V*&^6E+%G\XT;<22_.2U^"T7?)G;^/U!+ P04
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M$87'H8\J.>A_8^91="',]@KD#$%INE.A?U(S'C+0YW%!?=:/U$T\0,U^A.&
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M:Y]'23<PQ4A42/GY,-I\XIP-J;FCTS,*IF#Y:\@7FMB,#0FTI5,^9JT=5^"
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M.[/<=9Z32<T=V=H?-=63%$3.#14NZ-W)CH_IO,:.YH.&K1(C$=M,T4M0CVY
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MV4,RL?FK<\7B'=;%E?&S=XY_.=N[!%[3F5>N!&=,0+',0=GG6%&?F]!?D]U
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MZN+4>-53*XN-/PE^37CS,+$(3K!N8_?_)JO2K Y:F2IA!5U_3O5DM\-R\S*
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MW_[T[N.[+L>DK+(%D(-3U*04B4N#$+ R6A:PLOG^9 MY4#-JI6D- XTWV)2
M=8&*F:&XH4+PZ'S(9F\E<^B:WZSYS9K?K/G-H\"6K\QO:J4$31- =TN.N !-
MHDL6 '(W)*6>D&6QH3@2KW%5?ZS1!H8OM%0-4I7_#+\YV5UE_31/X>/T1ZTX
M_9+C]#=AI*T0K;\:@UBF NT^65D'HNM[-4?K,*'2AG$+.53=/NC_5UTY +#8
ME]E4SMS!',_XKA(DOT.N>[-J_/#HR/UQW;_P5-9<]SOBNH\)6UHG]CD7??MM
M?GD(S,U\FZR#165=U7!F-53$8%K\$\SXBU[MGKS]=24.7NN+JSR._#[QV7:K
M/#]:Y:%&UMY$V\J)35C\UDJK7^6AVX2F5=[?!MUWI<7XE,,ODW+6CLFF %.G
M\G","ARM% YCOA!2K<K0-=-9[KLF6=J[%:7(?+H-.ZJ:OFJY+!$(XX'&%8>E
M=>4P-PY]07\J%"%$$+G2@AR/WB,CDLJ2)4FZ<L[Q2&M!#ZNH\K$J1:Y4VJE=
M;.E=L7+B%]>*"X_F)S(A=5-MV7C#CJ>\2OQ1>DM6D<'UW&[':IFD:O*A<WPK
MFI'0>D3W]OZ$7902[S!),*H('OS,];&'C+.E!NA58W]<85% (D^QFH\#:$1%
M(=6:=^MUX-.DHK-BO0L#6> M]L*%IWIBCM1;5>)&2 _@C31.H].($Z%T,=ZZ
M9%=>6B$%\KN Y397!<@6TZG5=:(*] T9IP+XDH.<KXC\R+",RK*:A]PE /D0
MD*OL+*Z94L^0Y*G?*W1Y._(EPC[\K9.'%&8&J4&C4@"3A9< ZY4KC?=:6C.3
M&0Q0R)F/O<R%DQE[< ,(+6Z5@)INM+<.R[B;^KV6(@<4_\?&_YYD5Z^ I^P]
MV=U%R42^:8;- F!;,UYF:?Y,<M6*WVU'3A$ Q8"/I7%W2\4>%PK4(-0TH@AQ
M@ &083/%N:8C^'76-5.BU? D6M]S"M]8ZHME?.7TE'%(3_%T]@8'ZD.'K/LT
M"]R85+3V/3]$J_=W9)58^P+65HG'CBW?*O7F-C6?I604 Q>2-#'&;12J&60H
MZ^ZOI"X?5R3_->(3R92/0<Y5*<8R5:B"M,5S1\&C(<B/OQN#VM;'#_&T0>NF
ML+@@\[;$=)!+CSZ=7IQ_ZO:I^D%+>RJ-R1S)O'"6W1$EG18^Z51L?CPY=UL=
M/^,4]#[3AW$G+"_#[.TPR.9<F)?D%X$^%O%>)B4L[O1_!,&07^3B(?;$)7RP
M]&F'@? %R&4D0^-6Q_(JQ,@F1@ZKC#7/^FV0;$J%BI%S)F%QAA5 -3;%"%WW
MXJV T53JE41B<G^UA>'^\H[^HMRG^PV/_@0BM[3)".XP1\V&E7"\5$*Z2](S
M9[%0")D?1B#3>K $N*#T@(R0B&.EE0_3I1A$'[I,_CL<&R-2,:J"LR86XE')
M%A)M%*DJ%)T1AB:#Z#P7RVM[\]:"&)9[&,.ZLUD'8SBLPM#;8',)6(7;J1,>
MX%O2!F;S0=DU0A, RWE]OM;D<<ND5O0123"1Q$=21A67MIBF@$TD[UN,KEW4
MWQM1V9G)AQQCFU:6$S$P*V6088(4:OAPU$F%-'FB&F' ?J4X289A[F,0B4-:
M!^ YZ,A GLQ0H26AXV.7!ZBJYT.'P !C,[$,4<M3VIN",X-Y8+L6]1J#!@6*
M\20B6MN@4 '"%40%;C_$I$;2"_2AP&-MADCC:31#HQ6'W%?.&T6(8L8$$<H+
M^=8Y$6LY?RWGK^7\M9S_*+#E8<OYL=;EVU_%IC<^H[ML?R47U5%E+9OG)/!=
MFW;-H)L@0XEIFVPMQ]&1J2$+1J><1"MR#"_JB#XFMPR CXK4P'F##(/<CC@7
MN? ZR/TF[/T 4.$4I"0S*-XGVB8@"5O*?MQ,D@1^;K$).B_5D(4,7  G97HA
MR6>'\5H*S-IW);I[>DOLG\.YM-58OPU'93'+U9DW,9>0^&4<&O9$2V.[9) 9
M8!N#RA*?M0J$P64K>DC2^9>:*A^B.(Z[:IJ%*1F1];R"S>*U[(J71M_#-Q-M
M*I?-&@]Y(>L.3']/_Q9Q<:RL1IG] E0VQ4F.I B0X5P<H4P:=(+#/*]@I1^4
M0ECL! 4<U0,&:Y_MUTS4@Y-7I;>'IX@/J<<'#X]?MFJ0!V$,N, !R^,Q:H\T
MZA'ZX$TR*WV0(<,V^<U)"N>T7%S$11<N10.&H9?>'0ZW4!?"Q$B?\[SW_ =,
MS 2X  S/T"/@^%5XEH=E)0&DUUI9)Y4F5]-LUG :C0TF[XU-JK(P.:^> QR#
M#Z$MMM=B\O@3G!4[##)=@"Z4R]R@?T$#K1*;9Q_/MT+2W:P7+N;S SMJ$MSP
MA?*T,$6<X?;0S1 Y(+ZJUOQYM&$==OD7A%VN5:V'I52L5:VUJK56M1X,MCQL
M5>M#JU;+3UPBQH=)K#+]_MP(T8([L.KWBJ4]U+T263FV*8,0-L+24J#?!0-O
M+$71KASC"]:0#.D5$7PHV#Y!.&D^3R%GW!(*=F98MC37,Q3CR,D!XJL=SE@P
M<13AE.D!A_P$VZ:Q0Y!6!E6>L'GTAKWY*AB@95ES36X:V"7U:WC>@6.A2*>)
M3D$J=KVOV9QA[<>X*9YH=^_IWLO=YQQ/A&7) 8*;:E7(^R2@;$%=-^HFC"2;
M^"W]ND6@H\C>/L$;![$7Q'*4A1&0T3NQ!'RC_P,%?0]!""D)F?4Q<BX'",I8
M!V GX-38J[8?YH9:;U*,9G"T*0_&6H2W]X_U-8;!()* E)]VR;^Y.5(R*T<S
MMD3<MNA.[3*HBUW1T/$X6/GP&*>X" P)77A,/P[+@[V]'^JY>U^HTOV&9Y'Q
M*1Q)FQDG+@$O@5#B(GWEEG>.C!5G.AF5*G?D;6Q54_RH*LO%9[Q6W*Z*^$$#
MJ,+_60:C+!91]'8;/-6VNC9>1AYNK)1WXY[GJ3^5F<$B*K#_HNIGVHW0Q9)3
M7158QVH5ZKYHNH\4/(7A;^,J#]&:G[69!7,< .T'.1-/7G%QPP[[PQ@K:F"J
M:QJAX_WP5S071$2;,Q<4&?UQ*]+!,8VKK-0%0C!7*^J)CR9:S-!+&7UD[+?#
MRCX#C_X _&@F2$R5I5QRJ223 AM=?,4D9!Q70 ]*1-_*H<J-1@^%(:1]8#&1
M0'B=/2RX1 L'(1-@3V)@ _BQQ1#46L$'&GNEV)W6WF'-G6ZM];<.;%MK80_O
M5-9:V%H+^S9:6%L\?/E\[^6+%RP>/FP%[?U)=(%1M,G6:A%NG^$P@AF<4E>N
MY2=J&\7K^# <I2>PADP43(!A_R:Q9@IH1%EO=0'E9CED?C,?# C=Y$[S/H=5
M4]7^JX(]L]3A X+.8A3-!3.K3]%<#_L\,U-844YRX9DN3 A=XW80HU8W"/$^
MFN>_K*)XNV/M[7MI*^8Q_JF5IJ1=T&/Y4N!X<2L3)3Z>G+.CB,)T))=DZV*X
M#OKTM$E#M<I&#)3#O+)P6!UTIN)I(?Q@AA.E1VB>IRJX9*IX]>2'AO>#\C8P
MV#&(K3[ D-TEG#)!+XH7K??@R;/C,__<(U:?'Y??D=JNA(BUVHGHLUFBWAPC
MW&)U4]5HL]FJ3<IRO!V]W&/=:6GMI9E_K:7MAARPKWJN:U'W\3#OM:B[%G77
MHN[WX7 X/]FM!=J3W15CNCY#G,4);HM_4A11W4U&TDK@.!9.+A4GAS_O\I#P
M,(;3<":%"HF^7CY$)\,U.BX4D'^3475WK%&,C@:9H26X-O8B:RRM&J,!RRGD
MB8M15A)-1U<ZS17F*U,"<I)4XY!# 7P3RT9@Q!IPP[X5VV^^2!QZ7);\**UZ
M:9:S2T#4('^+!+$C9A]T4$"1<+9RJ-!DO?>JMS,G2]+-DJF:C.UB[V5O;^X1
MO&>5)R:ED"&?K(+1&S?%S?O:F6BFG"A*<Z'78]YNC_.'+4M%M:8$8E65E;[^
M@=.P*.=MF_@JKK2S!-+CMN$7%0?EAB:X##W&/] @ZJ$RP6\'&I9-$W$[B&#K
M1!2I4PGZ /(#$.E)6(^[38UKQAQ^C<)M'(?HT=:73EL24O3Y0N 7QP:M9;RU
MC+>6\=8RWJ/ EH<MXQU7R4CE(,U\J)P/@Y\![S3%:"8VCS\<;T4)$/]830)<
MVL.(FIW4P<]]I7*?EDA-#!)+MHJV+5/B$Q;8H<\I\Q^G?H5L[8-5<Q6)\<ST
M,^E*%U@DK#@(99PF&]DSR7SEU,SG#;=M(I')HO2 ;%*CGU+FBK>0^'X_*?H5
ML?]0AO(!")##$)"+[+RQ6!9:.7L 11@4.S&BYMGS6/7Z^?.Y#88.3!(DDF'#
MQ%N/A2:^*B1*4((QI14_!^D*GH4SZ**,BU<08WC6*0%?21X^1>/SA#L$@IBT
MTYEKB'RF49>0L9H8ED"Z3K**3+^Q-%BSSCMU!?I#+<<IELZP )G/"&9P; 6%
ML^76Z>N&8/FY!7E8\%TH7$62D\] ;]<RJTM8<04JBCG!WB(,MCQ<IY9Y ?O2
M*&+68O8R_)G/:4<DW[R=^L4RPO"LW]+67/NC=<SY X@Y7\3H;X#"BZ#TK1H#
MD8G_1O9^OZO"6*I::$#K!_').I_^@:S3AP0]D-5LKB2<1?)T=O:O)P]DY5L/
MY0AO[65[OTN!KQ[(2L31QXL'LI1( 1[(>AX*L# A>B"+$9]/B)X^D*4OK;O\
M#=9Q>[?FQ]=#_9Y#%JCN3U[^$<O4I#',![6')3U:8Z==WW68^S0+4W!U'GR2
M#/:4$;NTE7/#CNVB@ETW%?>U/=U(%Z"*1"MY11;Q1!8474WZM%>Y)S*KXA_>
M754W9B>719*H3%%-:.S+'!MABO?H=[B6V#"UXZL)::XV9@06!:;Z2E3AF(HE
M-T.%?,DO#L6(=9$Y'=@[%A(+@RUV+?8]U\DU0;I3MRZ*U&P0W?-J*==6]2V1
MHTJYO+HI!VU3'#5N'/A13[R;J-SW!I7#(9EQ*"2<.U3B&ZWZJN%TJ%8;S=TL
M880Q1>@J:BN6[>(+?%7JNLCPEG)0O+/VI=<UBBB''"T_P4DG?J]T<J5L*$7T
M-9T7WPT:7RXIM]N7&17FIJ[CCDT0] O6=N9:&TX$CV#,P/J/W1<OL99S1I81
MOJEJB('X3W<Y^8#-"GZV"!KAQJFS,8'"-74C']XR>0B5<E5=>(];QE-Y<:J)
M52@;T]O@2]\=Z#%"Q'TJ^T?2)T;]IOIP[*4XS?$=.LG'!]U1\_[[7,A"NP2U
MQE[:9-%66:SO<:&*DLU^>R%W!H#SU?[.CI"],=#&2X;G%-/6T&AM<BJ8EG!4
M C*P/G(YU*Y3S(HI?:]QK$%C\U"2CB(8X#%,T]Q\]>+%EMA[N=-]LO/\%3V\
M^>KETRWQ;/=Y%U;PHD.VLI"9$\QT<=[38S]K-"/22F![+YZ^?/'LZ?.>.*?R
M%!HP$%MX2^!1F3.Q:K[O) [DFRZ_66W> 1^BS+2)U!G1:N^[/R5>8"R[H#%K
M"_LHL'N?6W;?VFREF?^$[*;D<5I5R+V@UA.'0%F @^D)N?,!U6>!>?L51\I0
M+]/DH@D&\"!F%T6C!\7AUK4^?+/Y./>:9-S=28,:D1-7?GP4@I?MJJ*EB+#9
M]_D/!PB8W1%/M_L$EHCIEBB8>1,N.3=__-ONRV=P;3#*&^*+5%31:E5B^9LY
M W]#ODRU2PR[IAI6?G94.>)J&EU?0'669J#VQ&G);B]'R=Y)[%218.&K;E*5
M-*/*_YA14BE ?*.<+GN:J$F(;V6"?%A3+B=+E6*3 K?@KRTD/&-8J_\(+GR+
MQ@,DE)KK; $B9MQ]A/-0*0$<,[JU0WDY5BKE"KR&ZO%@OB.WQ4B2REI\>>ZX
M>/$=<=H]LNK4KUI-3.:+^E!*>C:4ZFX/R-$HD^,9D&*@NR@-ZWPD;5IJ[<D+
M7..+G0,XA#&VKO U2..)PFFZD#D<:HOU6I0EJC<4:!9:5. )4UA3B*^6U*[%
MJI%/#\ @*Z _VC2(;>WS>[6#\BV116Q0 K^N*=**%.F&M.W3//DKC_#>?0@+
MFV&2TPCL1QVKKTV#TH0&0:FB)C"^V0M%KG'UJ@%@]O'EZ=F6[U0$X.:5+X;E
M2,V\!HH$;QY5 _PW<%TNH!&.%TP#ZJ81? 5?*@OL:5/P*T93@),#58*8%F+5
M.K[_4EY:DY$N"_<5>A71@CI+>XL4NN <F01=D$AO*5?8)R][@P:E)H^ OH*
M. CJY='A)W$)ISBN<E/Z:FSQ%F*E+B:$%((J:5WHA65A%&0@ZP6E^'[]6NCA
M%+RS+#IR=3)0D^MV3B-%JK*0*; !BH*M*RV2+L7&"J(INI;FA;P-2PI.-)G
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M"5*ERD5I;2V)@4 L9IP^BN((M\=X,PR7-FXU;""ORU.64XPK4R]9G0[Y=BJ
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D;"UE>#DY,E\Y-RYH=&U02P4&      8 !@"% 0  ,W(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
